Get started

Cannabis

TLRY - Pump, Dump, RepeatTilray's recent bubble pop has a lot of shareholders in panic mode. Despite the massive spread and a 60% drop from the high in just two days, an incredible amount of speculation still remains in the cannabis sector. What makes TLRY different than other cannabis stocks is the incredibly low float of ~18M shares, which serves to amplify the effects of speculative trading (in both directions). Compare the float to the average daily volume of 9M shares, and you will see what I mean. TLRY touched the 38.2% fib level after market Friday, and according to the 5/26 MACD has some room left to drop. I set my fibonacci bounds to the high near $300, and low at listing price around $20. It is difficult to tell how far down something this volatile will go, but according to the setup we can expect a bounce around the $60-$80 price range (likewise, when the 26-EMA touches $100, a previous support/resistance level). There will likely be a mini-bounce around $100 but I do not count on it sticking. 5/26 MACD indicates we have at least a few days before this thing will start to find a bottom. Implied volatility will be crushed as standard deviation reduces from the averaging of pump and dump outliers, which will in turn lower option premiums. Planning to buy some covered calls if the setup bites, otherwise reassessment will be necessary. Worst case scenario for this setup is that it hits the $60-$80 range and flattens, crushing option premium even further (which can be mitigated through use of covered calls combined with put credit spreads if necessary). Recreational legalization in Canada on Oct. 17th along with TLRY being the first Canadian cannabis company to obtain operational license within the U.S. add fuel to the fire that is speculation. Also of note is the disruptive impact that cannabis companies will have on traditional pharmaceuticals, a market holding ~$1.1T capitalization. There is also the potential for more states to legalize cannabis for either recreational/medical use. These all fuel speculative interactions within the market. A note on long term TLRY trades: there are 10M+ shares in lockup until January 2019, which will become public sometime then. I do not suggest holding any positions into January as the market will likely react violently to the increase in float.
NASDAQ:TLRYLong
by Derivati_Capital
5
CBIS Pulse is faint but pulsing with research quivers...Watch CCI momentum with MACD here. . . future profits and earnings TBD. Await patents and studies. Expect they'll eventually have to sell the farm here to pay for all the cannabis / hemp studies. Ent Value / Mkt Value is 1.02. A new medical advisory board for new medical products. One patent issued 2017 for treatment of neurobahaviors and could lead to positive litigation...TBD. This is a watch and wait scenerio for entry...@pokethebear Studies mainly on Endogenous cannabinnoid family, which are produced in our bodies, vs natural occuring phytocannabinoids from cannabis, or made synthetically. CBIS studies may be specific to proving scientific value as neuromodulators and their absorption/binding to the our bodies fatty lipid areas/tissues and possibly dosage. If there's a pHD in the room to help confirm wording here, but the study and health benefits of CBD, CBDA, CBG, CBGA, THC, THCA, 9-THC, 9-THCA, 8-THC and THCV. Aka proving the science to the F&DA each endocannabinoid does something specific (sleep aid, pain releif, epileptic med., ADHD/ADD med., reduce inflamation, anxiety, psoriasis (skin inflammation), slows bacterial growth, inhibit cancer cells (first study published), stimulate appetite, reduce vomiting/diarrhea, and several other benefits.
CLong
by Pokethebear
Support Level for TilrayTilray INC NASDAQ:TLRY , is The Super Star in the Cannabis industry currently. Yesterday, the stock had a thrilling ride, as it jumped to $300, going as low as $151.40 per share and finally closed at $214. Tilray's stock price has jumped, since its IPO, by over 600%. These type of returns are rare, very rare and will always gain attention. As Tilray, is likely to have more days of volatility, I am looking at a potential exit point. If Tilray breaks below $151.40 and stays below $151.40 it will be trigger to potentially exit this trade
NASDAQ:TLRYLong
by CamariEllis
About to get stoned...Shares of TLRY, and many other pot stocks for that matter, have been on fire lately. While I've made good money along the ride, its just getting ridiculous at this point. This company went public exactly 2 months ago today.. the IPO price was $17. In 8 weeks time, it's up over 1300%! That's incredible for those that got in early, but its a clear sign of ignorance to be chasing it up here now. If you aren't taking at least some profits, you're either greedy or mentally ill. While I think there's a lot of growth potential in the weed space, as evidenced by companies like STZ and KO getting invested, people need to be patient and let the prices come back down to earth. I'm actually shorting this thing via long put options (the options are pricey, too!). Specifically, I bought Sept. 28 $55's in one account, and longer dated October $120's in another. Yes, it's ballsy move, but this blowout volume today may be a capitulation point. Take a step back and smoke a blunt or 6 while you wait for this thing's buzz to wear off! And please don't be an idiot and chase this thing up here!
NASDAQ:TLRYShort
by EchoAlphaBravo
Tilray most likely to hit ~$174aicody.com Company Summary Tilray, Inc. (NASDAQ: TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients in ten countries spanning five continents. Tilray has reported financial results for second quarter of 2018 and six months ended June 30, 2018. “We are very pleased with our strong start to 2018. Tilray is well-positioned to continue to pioneer the development of the global medical cannabis market and to become a leader in the adult-use cannabis market in Canada,” said Mr. Brendan Kennedy, President and Chief Executive Officer of Tilray. “In the second quarter, we generated significant revenue growth as a result of our global strategy, our multinational distribution network and our commitment to research, innovation, quality and operational excellence. Second Quarter 2018 Financial Highlights Revenue increased to $9.7 (C$12.7) million, up 95.2% compared to the second quarter of last year. The increase in revenue was driven by increased patient demand in Canada, sales to other Licensed Producers and international sales. Total kilogram equivalents sold increased 745 kilograms to 1,514 kilograms, or 97%, compared to the prior year. Average net selling price per gram increased from $6.20 to $6.38 (C$8.12 to C$8.36) for the three months ended June 30, 2017 and 2018, respectively. The increase was primarily due to growth in higher potency product and extract sales, partially offset by an increase in wholesale revenues. Net loss for the quarter was $12.8 million compared to $2.4 million for the second quarter of 2017. Net loss includes non-cash stock compensation charges of $5.6 million compared to a $35 thousand charged in the prior year period. Adjusted EBITDA was a loss of $4.7 million compared to a loss of $1.9 million the second quarter last year. The increased net loss and Adjusted EBITDA decline was primarily due to the increase in operating expenses related to continued growth, expansion of international teams, and costs related to financing and the initial public offering (“IPO”). Business Highlights in 2018 to date: Successfully completed IPO in July whereby 10.350 million shares of Class 2 Common Stock were sold at an initial price to the public of $17.00 per share. The Company received net proceeds of $163.6 (C$216.9) million after the underwriting discount. Net proceeds will be used to fund the build out of cultivation and processing capacity, repay outstanding principal and interest under the Privateer Holdings debt facilities, and for future acquisitions and working capital. Prior to the IPO, completed Series A funding of $55.0 (C$69.2) million from leading institutional investors. Signed agreements to supply cannabis to adult-use consumers in seven Canadian provinces and territories (British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, the Yukon territory and the Northwest Territories). Entered into a strategic agreement with Sandoz Canada, a division of Novartis, to collaborate on the creation and sale of co-branded and co-developed non-combustible medical cannabis products. Signed agreement with Shoppers Drug Mart Inc., Canada’s largest pharmacy chain with more than 1,200 pharmacies and expect to supply Tilray products following approval of Shoppers’ application to become a Licensed Producer. Signed binding letter of intent with Pharmasave, one of Canada’s leading independent pharmacy chains with more than 650 pharmacies, which Tilray anticipates will allow it to supply Pharmasave stores with Tilray products contingent upon a change in laws that permits Canadian pharmacies to distribute medical cannabis to patients. Completed exports to Argentina, South Africa and the United Kingdom, making Tilray products available in 11 countries on five continents. Launched High Park Holdings Ltd., Tilray’s wholly owned subsidiary formed to serve the pending adult-use market in Canada with a broad-based portfolio of cannabis brands and products. Announced the launch of the CANACA™ brand, a new cannabis brand celebrating Canadian roots, values and this historical moment in Canada as the country becomes the world’s first G7 nation to federally legalize cannabis through adult-use legalization. Announced clinical study results of Tilray® 2:100 product showed promise in Canada’s first pediatric study of mixed THC/CBD medical cannabis oil for children with drug-resistant epilepsy. Statistics Shares Outstanding: 76.5M Avg Daily Vol: 8.5M Market Cap: 14.08B 52-Week High: $151.18 52-Week Low: $20.10 Forward PE: NA Annual Div/Dividend Yield: $0.00 / 0.00% Annual Rev: 23.1M Inst Own: 0.0% 1-Month Return: NA 3-Month Return: NA Next Earnings Report Date: 08/29/2018 Earnings ESP: -0.18 Revenue Per Employee: $85,912 Money Flow Ratio: 1.08% Profitability Revenue Growth: 62.5% (Sector Average 3.3%) Gross Margin: 53.0% (Sector Average 62.4%) Return on Equity: NA (Sector Average -19.2%) Net Margin: -52.9% (Sector Average -10.4%) Debt Current Ratio: 1.1 (Sector Average 2.9) Debt-to-Capital: 230.5% (Sector Average 25.8%) Interest Funding: -12.5% (Sector Average 0.3%) Interest Coverage: -11.6 (Sector Average -4.7) Dividend Dividend Growth: NA (Sector Average 5.5%) Dividend Payout: NA (Sector Average 66.7%) Dividend Coverage: NA (Sector Average 2.1) Dividend Yield: NA (Sector Average 0.00%) Top Peer Companies Akcea Therapeutics Inc (AKCA) Akorn Inc (AKRX) American Cannabis Company Inc (OTCMKTS: AMMJ) Amphastar Pharmaceuticals Inc (AMPH) Aphira Inc (TSE: APH) Aurora Cannabis Inc (TSE: ACB) Cambrex Corp (CBM) CannaRoyalty Corp (CNSX: CRZ) Canopy Growth Corp (CGC) Corcept Therapeutics Inc (CORT) Cronos Group Inc (CRON) Emergent BioSolutions Inc (EBS) Hydropothecary Corp (TSE: HEXO) Innoviva Inc (INVA) Maricann Group Inc (CNSX: MARI) Medmen Enterprises Inc (CNSX: MMEN) MedReleaf Corp (MEDFF) OPKO Health Inc (OPK) Pacira Pharmaceuticals Inc (PCRX) Theravance Biopharma Inc (TBPH) VIVO Cannabis Inc (ABCCF) 12 Month Price Target Mean: USD$115.05 High: USD$174.33 Low: USD$90.32 Revenue Growth Revenue increased to $9.7 (C$12.7) million, up 95.2% compared to the second quarter of last year. The increase in revenue was driven by increased patient demand in Canada, sales to other Licensed Producers and international sales. Earnings Surprise Positive (+18.4%)
NASDAQ:TLRYLong
by aicody
2
Is Shopify going to be the Amazon of the Dope Game?Rumors Shopify is a platform that allows small businesses to launch e-commerce websites, so who knows online retail better than them? shopify-weed-biz.jpg Shopify SHOP:CN is a Canadian e-commerce powerhouse. Kylie Jenner made almost a billion dollars and guess which platform is credited with helping her do the most in the make up game? In February of this year news came that it would be partnering with the Ontario Government to handle online cannabis sales with the provincially run Ontario Cannabis Retail Corp. This is probably one of the better moves by the Government, because they are known to be literally the worst at making business decisions. ocs_primary_logo_reg-768x292.jpg I mean, who pays $700k for a logo that looks like this? Bruh, I could have done that shit in paint. Holy Face Palm Emoji Batman. OK, so there was some other marketing wrapped up in that deal but let’s just say that Ontario tax payers and blunt smokers alike should have been happy about the Shopify news. Anyways, the news in Feb sent SHOP stock soaring to new highs and was baked into the price at the time. After a recent pullback, the stock is now moving back to its all time highs. This is because there are many new articles coming out about the impact that Cannabis will have to SHOP’s bottom line. At this time, several Canadian provinces have picked Shopify to run their e-commerce websites and the company has also signed deals with marijuana companies including Canopy Growth Corp. This has the stock up about 3% at the time of this writing. This is an abbreviated synopses of my thesis for investing in this stock. A detailed and rigorous analysis relying on trusted information from various sources and analysis tools learned over time is always present in the decision making of these equity choices, but omitted for proprietary reasons. Fundamentals Everybody knows that Cannabis is the new frontier. The once taboo “drug” has now become mainstream, and investors cannot wait to jump in to companies that produce, refine or sell it on the retail level. Shopify is not a cheap company by any traditional metrics. We normally like to buy good companies that are growing fast when they are cheap, so caution is warranted here. However, this company is doing 9 Billion dollars in sales a quarter and is growing at 56% a year. That being said, the numbers are growing like weed (ha), even without the company slingin’ herb on the side. The potential for this to entice investors to jump in the stock and set the stock a blaze. Ok, I’ll stop. If these deals fall apart it is difficult to justify a valuation of over $120. In a down market this kind of stock can fall to $40-50 easily. The trading range on this stock is wider than my waistline after Thanksgiving Dinner. Technicals Technically, the stock has consolidated after a pullback from what looked like a double top in early august and has reversed that pattern, which is typically very bullish. This is because when there’s a technical pattern that easy to recognize, technical traders rush to short the stock. As that pattern get’s invalidated, those short sellers have to cover their positions and buy back the stock. See the chart for a quick TA and trade breakdown.
TSX:SHOPLong
by LIfestyleConnect
Will Coca-Cola be the next big player in the Cannabis Market?Aurora ACB:CN is a Canadian Cannabis stock that is up 15% today on news it’s in talks with Coca-Cola, about starting a partnership in the weed game. Imagine going to the corner store or wherever beer, wine & liquor are sold and seeing Cannabis infused drinks beside your Bud Light or Corona. I’ve been asked by many of my subscribers to publish my picks, in real time. Unlike most pundits, analysts and personalities, I will be doing so in an open and transparent way, so that I show my process, win or lose. One thing for sure is that Coca-cola does it BIG, so any deal for Aurora will be huge and have immediate impact on the companies earnings. MOST CANNABIS STOCKS ARE OVER VALUED AND OVER HYPED. THIS IS A RISKY TRADE. PLEASE CONSIDER RISK OF LOSS BEFORE CONSIDERING TO PURCHASE THIS STOCK WITH ME. PLEASE ALSO RISK ONLY WHAT YOU CAN AFFORD TO LOSE. At the time of this writing, Aurora is trading at $9.86. I have purchasing 2000 shares on the open market. Here are my trade parameters, for your consideration. MY BUY PRICE: $9.73 BUY RANGE: $8.00 - $10.50 1ST TARGET: $24.50 - $15.90 2ND TARGET: $28.00 - $32.75 (if a deal actually gets done) STOP LOSS: $7.20 - $7.60 Notice: Stocks like this can move very quickly, so experienced traders may want to use a mental stop zone, so they are not whip sawed out of a trade. Inexperienced traders may choose to put a simple limit at $7.50 and not re-enter the trade if stopped out. If the rumors fall apart, I will be exiting the trade at those prices. While Aurora has not gone hyperbolic like other stocks in the sector such as Tilray (TLRY:US) and Canopy (WEED:CN, CGC:US), it is important to note it should not be worth more than $3, even with a generous fundamental valuation. This sector is on fire and completely controlled by momentum traders and speculators.
TSX:ACBLong
by LIfestyleConnect
UpThere are no chart patterns to stop this, so I have no opinion. I sold everything 2 days ago with a nice profit. Before the close today I bought a stake again as it looks strong. It busted thru the gap with no problem. So I'm in the green a little and my stop is set for protection. I don't mid taking small losses. If it hits the stop and then looks good again, I'll get back in. But me thinks this will float higher. Something is going on.... we'll find out later as usual. It's not the Oct 17 date either, thats been known for a long time. Maybe its the license, maybe its a take over? Maybe its a proftable trade!!
N
by AnotherBrian
3
$HIPH Breaks out on Massive coverage by Respected MJ News SourceHYDRO INFUSED CBD WATER: Huge Potential Benefits For Millions of Athletes NEW YORK, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Cannagreed.com News Commentary American Premium Water, Corp. (OTC:HIPH) BREAKING NEWS: LALPINA HYDRO CBD WATER can go a long way towards administering doses of cannabinoid (CBD) for those who deal with chronic ailments such as, inflammation, pain and anxiety disorders. There are also huge potential benefits for athletes who may not only use LALPINA to hydrate, but also to minimize the inflammation, pain, and stress that physical activity places on the body. The Company began selling its LALPINA Hydro CBD product August 27th on its website. The Company has been able to procure a domestic manufacturer who can provide the supply to meet the growing demand of LALPINA Hydro CBD. “With a new product like LALPINA Hydro CBD, there were some teething issues in the ramp up to production. This product is a market frontrunner right out the gate considering the lack of a comparable product currently on sale. Unlike the other CBD waters that are currently at retail, the molecular structure of LALPINA Hydro CBD allows for greater bio availability which leads to a greater & quicker absorption rate compared to regular CBD oil or CBD water. The Company will need to use less CBD to create a greater benefit, which will allow for a higher gross margin per unit,” added CEO Ryan Fishoff. LALPINA HYDRO CBD could improve workouts by providing hydration and muscle relief. Several studies have shown CBD could provide workout recovery health benefits thanks to its analgesic, anti-inflammatory and neuroprotective properties that include: Anti-Inflammatory Muscle Spasm Relief Protection of the Heart, Lungs and Brain Reduction of Nausea Increases in Appetite Sleep Aide Recent reports indicate that the CBD market is estimated to grow 700% by 2020. Hemp Business Journal, a market intelligence research firm, projects that the CBD market will grow to $2.1 billion by 2020, an astronomical jump in value compared to the 2017 CBD market value of $202 million. Athletes, amateur and professional, are a segment that is helping drive this exponential growth. Research has shown that in addition to physical effects, CBD could have positive effects on well-being, reduction in anxiety, and a tangible impact on mental recovery, all traits that have appeal to athletes at all levels and could lead to CBD infused water becoming part of athletes regimen. The Company has been working with The Brewer Group (www.thebrewergroup.com) and CEO Jack Brewer to help recruit current and retired professional athletes to promote LALPINA Hydro and LALPINA Hydro CBD beverages. Studies have shown that there are many potential health benefits from ingesting hydro nano infused products, including short term benefits to enhance workouts and aid in recovery. The Company is also working with Mr. Brewer on initiatives with current and former NFL players with the Company’s LALPINA Hydro CBD beverage. Mr. Brewer, a 6-year National Football League veteran and CBD proponent, has the network to assist the Company’s efforts to educate the public about the benefits of hydrogen and hydrogen infused CBD. Mr. Brewer was instrumental in getting LALPINA placed at events and parties at the Super Bowl in Minneapolis earlier this year. The Company and Mr. Brewer see the potential for LALPINA Hydro CBD to be an all-natural replacement for opioids, which would benefit retired players, whose struggle with opioid addiction has been well documented. And with the removal of CBD from the World Anti-Doping Agency’s list of banned substances, in addition to the imminent passage of the Farm Bill Act, large scale CBD use by current athletes is not very far away. “Working with Jack (Brewer) and the Brewer Group has been great for the Company. He has opened many doors for the Company, specifically in distribution and exposure. I am excited to work with all the athletes that are in his network to promote and educate the public on the benefits of CBD infused beverages. Incorporating retired and active athletes will be a game changer in my opinion, and I’m excited about all the content that Jack’s team will be creating to help us achieve this goal,” added Mr. Fishoff Based on the demand that the Company has received for it’s LALPINA HYDRO CBD beverage, the Company has had exploratory discussions about developing a THC infused hydrogen infused beverage. Developing a THC infused beverage would allow the Company to enter the exploding cannabis market. www.otcmarkets.com
OTC:HIPHLong
by StockGuild
Next Leg up on $HIPH Confirmed Closing the Week Nicely GreenIt seems the market is finally realizing the full potential of CBD/Hemp products under the cornucopia that is $HIPH The website which is being fully revamped and updated will be showing a line of products that may include other products from acquisitions $HIPH has already undertaken and brought into the company's fold and future acquisitions. The CEO Ryan Fishoff has been working dutifully to get the company up and running again, future uplistments to Pink Current then OTCQB along with several other product lines in store which will run into the CBD and Hemp niche markets. I predict a very nice rebound here next week and possible new Highs as we head into the future updates and of course the impending MJ Rush later this year.
OTC:HIPHLong
by StockGuild